{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-003444","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.843909+00:00","generated_at":"2026-05-17T05:19:12.813039+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Silexion reports SIL204 shows up to 99.7% inhibition across 11 human cell lines, first gastric cancer data","bullets":["SIL204 achieved 83.5% to 99.7% inhibition at nanomolar concentrations (IC50 23.4–85.3 nM) in 11 lines from 5 cancer types.","Highest activity: 99.7% inhibition in NCIH2009 lung cells (G12A mutation); first gastric cancer data showed 89.2% inhibition (G12D).","Pancreatic G12R (17% of cases) showed 91.5% inhibition (IC50 31.5 nM) in KP2 cells; expanded colorectal validation in HCT 116 (G13D).","SIL204 now confirmed active against G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations.","Phase 2/3 trial planned H1 2026; regulatory submissions to Israel MoH in Q4 2025 and EU in Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-003444","json":"https://secwatch.observer/filing/0001178913-25-003444.json","markdown":"https://secwatch.observer/filing/0001178913-25-003444.md","text":"https://secwatch.observer/filing/0001178913-25-003444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325003444/0001178913-25-003444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325003444/zk2533822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:19:12.813039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}